Linical (2183) Q1 2026 earnings summary

Executive summary

• Consolidated net sales for the three months ended June 30, 2025, declined 10.3% year-over-year to ¥2,626 million, mainly due to revenue decreases in the US, South Korea, Japan, and China, despite gains in Europe and Taiwan.

• Operating loss increased to ¥104 million from ¥66 million in the prior year period, as profit increases in Europe and recoveries in Taiwan and China were offset by declines in the US and continued losses in Japan and South Korea.

• Net loss attributable to owners of parent was ¥177 million, compared to a loss of ¥82 million year-over-year.

• Comprehensive loss was ¥205 million, reversing from a comprehensive income of ¥287 million in the prior year.

Financial highlights

• Net sales: ¥2,626 million, down 10.3% year-over-year.

• Operating loss: ¥104 million, compared to a ¥66 million loss in the prior year.

• Ordinary loss: ¥164 million, compared to a ¥47 million loss year-over-year.

• Net loss: ¥177 million, compared to ¥82 million loss in the prior year.

• Gross profit for the quarter was ¥709 million, down from ¥724 million year-over-year.

Outlook and guidance

• Full-year forecast for FY ending March 2026: net sales of ¥11,200 million (up 7.3%), operating profit of ¥300 million, ordinary profit of ¥320 million, and net profit of ¥150 million.

• Net income per share projected at ¥6.64.

• Dividend per share planned at ¥16.00, unchanged from the previous year.

• Growth expected from the US and recovery in Europe, Japan, and Asia.